Gilead suspends access to remdesivir due to overwhelming demand for the experimental COVID-19 treatment
Gilead has announced that it is in the process of transitioning from individual “compassionate use” requests to “expanded access” to both accelerate access to remdesivir for severely ill patients, and enable the collection of data from all participating patients.
Source:
Biospace Inc.
SPS commentary:
Remdesivir is a small molecule monophosphoramidate prodrug of an adenine nucleotide analogue (NUC inhibitor) identified in Feb 2020 by the WHO as the most promising candidate for treating 2019-nCoV acute respiratory disease.